Daoyong Ni

Prof. Dr. Daoyong Ni


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2024 in ACS Omega
Verified
Journal Article
Open access
CXChenxin Xu
Chenxin Xu
YCYinghua Chen
Yinghua Chen
ZZZhuoen Zhou
Zhuoen Zhou
YYYing Yan
Ying Yan
WFWenying Fu
Wenying Fu
DNDaoyong Ni
Daoyong Ni
Lung cancer is one of the leading causes of death. Celastrol is a natural product that has shown anticancer activity but has not yet been applied in clinical settings due to its narrow therapeutic window. In this study, we discovered that celastrol stimulates an abnormal rise in the reactive oxygen species (ROS) level in lung cancer cells and that the ROS scavenger N-acetylcysteine (NAC) could counteract the cell death caused by celastrol. At the same time, celastrol upregulated the expression of cytoprotective transcription factor Nrf2 and its downstream proteins, which are effective in preventing the oxidative damage caused by ROS accumulation. Notably, we found that the overexpression of Nrf2 enhances the tolerance of lung cancer cells to celastrol and that lung cancer cells H460 with a Keap1 mutation are insensitive to celastrol. This indicates that the increase in Nrf2 contributes to the survival of lung cancer cells. Thus, we brought in an Nrf2 inhibitor ML385 to suppress the activation of Nrf2. We found that when ML385 and celastrol were added together the survival rates of lung cancer cells decreased more and the detected ROS level became much higher compared to treatment with celastrol alone. We also discovered that ML385 suppressed the expression of HO-1 and GCLC, which amplified celastrol-induced ATF4/CHOP-dependent endoplasmic reticulum stress (ER stress). Above all, our study found that ML385 enhanced celastrol-induced increases in ROS and ER stress, leading to lung cancer cell death. This research provides a potential strategy for the preclinical investigation of celastrol.

31 March 2024 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
XSXin Shen
Xin Shen
YXYiqun Xia
Yiqun Xia
HLHui Lu
Hui Lu
PZPeisen Zheng
Peisen Zheng
JWJunqi Wang
Junqi Wang
DNDaoyong Ni
Daoyong Ni
Thioredoxin reductase 1 (TrxR1) has emerged as a promising target for cancer therapy. In our previous research, we discovered several new TrxR1 inhibitors and found that they all have excellent anti-tumor activity. At the same time, we found these TrxR1 inhibitors all lead to an increase in AKT phosphorylation in cancer cells, but the detailed role of AKT phosphorylation in TrxR1 inhibitor-mediated cell death remains unclear. In this study, we identified the combination of AKT and TrxR1 inhibitor displayed a strong synergistic effect in colon cancer cells. Furthermore, we demonstrated that the synergistic effect of auranofin (TrxR1 inhibitor) and MK-2206 (AKT inhibitor) was caused by ROS accumulation. Importantly, we found that ATM inhibitor KU-55933 can block the increase of AKT phosphorylation caused by auranofin, and exhibited a synergistic effect with auranofin. Taken together, our study demonstrated that the activation of ATM/AKT pathway is a compensatory mechanism to cope with ROS accumulation induced by TrxR1 inhibitor, and synergistic targeting of TrxR1 and ATM/AKT pathway is a promising strategy for treating colon cancer.

9 October 2025 in Organic Letters
Verified
Journal Article
Closed access
XZXinyu Zhou
Xinyu Zhou
JLJiayi Liang
Jiayi Liang
FDFengyin Duan
Fengyin Duan
LWLijin Wang
Lijin Wang
PZPeng Zou
Peng Zou
XLXiaorong Li
Xiaorong Li

1 August 2025 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
HLHui Lu
Hui Lu
WFWenying Fu
Wenying Fu
YXYiqun Xia
Yiqun Xia
YYYing Yan
Ying Yan
CSChongchong Shu
Chongchong Shu
DNDaoyong Ni
Daoyong Ni
Adagrasib, a KRASG12C inhibitor, recently received accelerated approval from the US FDA for the treatment of patients diagnosed with KRASG12C-mutated non-small cell lung cancer. Although adagrasib has demonstrated excellent clinical efficacy and good safety, the molecular mechanism underlying the antitumor activity of adagrasib remains elusive. Here, we report that adagrasib treatment markedly inhibited the growth of cells harboring the KRASG12C mutation, whereas the non-KRASG12C cell lines H1299 and PC-9 were also sensitive to adagrasib, indicating that adagrasib exerted off-target effects. Mechanism studies indicated that adagrasib treatment reduced the level of NRF2 via upregulating its ubiquitination, and NRF2 overexpression can reverse the adagrasib-induced cell death in H23 and H1299 cells. Furthermore, adagrasib treatment significantly increased the cellular ROS level and thereby activating autophagy and AKT signaling pathways in H23 and H1299 cells. Importantly, combination of adagrasib with panobinostat demonstrated enhanced antitumor activity in vitro and in vivo. Overall, our data elucidate a novel mechanism of adagrasib, which will be critical for the clinical application of adagrasib.

23 October 2025 in Toxicology and Applied Pharmacology
Verified
Journal Article
Closed access
HLHan Lin
Han Lin
YYYing Yan
Ying Yan
CQChenyu Qiu
Chenyu Qiu
JWJunqi Wang
Junqi Wang
WFWenying Fu
Wenying Fu
DNDaoyong Ni
Daoyong Ni

9 September 2025 in Cancer Research and Treatment
Verified
Journal Article
Open access
PDF file
YYYing Yan
Ying Yan
CQChenyu Qiu
Chenyu Qiu
WFWenying Fu
Wenying Fu
CSChongchong Shu
Chongchong Shu
CXChenxin Xu
Chenxin Xu
DNDaoyong Ni
Daoyong Ni
Synergistic Anticancer Effects of Lenvatinib and Celastrol via ROS-Mediated ER Stress and JNK Signaling in Colon Cancer Cells